Track topics on Twitter Track topics that are important to you
TUCSON, Ariz., Aug. 6, 2015 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a provider of instruments and reagents for molecular profiling applications, today reported financial results for the three and six months ended June 30, 2015.
Recent Accomplishments & Highlights:
"We are pleased with our accomplishments in the first half of 2015 and most importantly have several growth catalysts on the horizon," said TJ Johnson, President and Chief Executive Officer. "We are focused on our growth initiatives in product expansion and market development in these early stages of the democratization of molecular profiling. We believe there is increasing awareness of the strength of our platform as evidenced by our recent inclusion into the WIN Consortium."
Second Quarter 2015 Financial Results:
Revenue for the second quarter of 2015 was $0.8 million. Net loss from operations for the second quarter of 2015 was $6.5 million, compared to $3.7 million for the second quarter of 2014. Net loss per share was $(1.73) for the second quarter of 2015 and $(49.62) for the second quarter of 2014.
HTG ended the second quarter with $11.2 million in cash and cash equivalents. The company also had $32.9M in short and long-term available-for-sale securities.
2015 Strategic Priorities:
HTG is focused on the following priorities for the remainder of 2015:
1. Increase product offerings with four new HTG EdgeSeq panels including a comprehensive ImmunoOncology panel
2. Complete key milestones per Illumina agreement with our IVD lung panel program, targeting a 2016 submission to FDA
3. Enhance commercial productivity with acceleration of instrument placements driven by menu expansion, implementation of a CRM and new customer data support tools
4. Accelerate market development efforts with key thought leaders and research collaborations
5. Initiate development on new HTG EdgeSeq instrument targeting smaller lab market to drive decentralization
Conference Call and Webcast:
HTG will host an investment community conference call today beginning at 4:30 p.m. ET. Individuals interested in listening to the conference call may dial (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers, conference ID 72827218, or access the webcast on the investor relations section of the Company's website at: www.htgmolecular.com. The webcast will be available on the Company's website for 90 days following the completion of the call.
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics' mission is to empower precision medicine at the local level. In 2013, the Company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with our business, capital resources and strategic and growth initiatives. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the Quarter ended March 31, 2015. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
-Financial tables follow-
|HTG Molecular Diagnostics, Inc.|
|Statements of Operations|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Product||$ 648,347||$ 75,139||$ 1,375,785||$ 445,146|
|Cost of revenue||834,949||615,523||1,729,575||1,257,934|
|Selling, general and administrative||3,726,490||2,429,388||7,165,759||4,506,190|
|Research and development||953,222||865,540||1,641,437||1,723,023|
|Total operating expenses||4,679,712||3,294,928||8,807,196||6,229,213|
|Loss from change in stock warrant valuation||(2)||(628,643)||(56,322)||(239,683)||(56,322)|
|Interest expense, net||(465,006)||(56,436)||(944,306)||(130,949)|
|Other income (expense), net||(3)||(634,583)||4,008||(634,583)||1,104|
|Net loss before income taxes||(6,452,342)||(3,684,826)||(10,540,477)||(6,512,416)|
|Accretion of redeemable convertible preferred stock discount, issuance costs and dividends||(418,465)||(1,100,048)||(1,328,594)||(1,914,543)|
|Net loss attributable to common stockholders||(6,870,807)||(4,784,874)||(11,869,071)||(8,426,959)|
|Net loss per share attributable to common stockholders, basic and diluted||$ (1.73)||$ (49.62)||$ (5.49)||$ (87.39)|
|Shares used in computing net loss per share attributable to common stockholders, basic and diluted||(4)||3,973,055||96,440||2,163,295||96,426|
(1) The Company recorded a $168,000 inventory reserve in Q2 for excess HTG Edge reader inventory. This reserve is the result of a higher demand for our HTG EdgeSeq products, first introduced in 2014, which do not utilize the reader technology.
(2) The Company recorded non-cash stock warrant valuation adjustments due to the increase in fair value of its preferred stock warranty liabilities
(3) Includes $705,217 of non-cash expense in Q2 from the loss on settlement of convertible notes.
(4) Reflects an increase in weighted average common shares outstanding during the period as a result of our May 11 IPO.
|HTG Molecular Diagnostics, Inc.|
|June 30,||December 31,|
|Cash and cash equivalents)||(1)||$11,171,021||$ 3,613,392|
|Short-term available-for-sale securities, at fair value||(1)||18,456,590||--|
|Accounts receivable, net||554,181||801,125|
|Prepaid expenses and other||767,735||112,035|
|Total current assets||33,361,620||6,212,366|
|Long-term available-for-sale securities, at fair value||(1)||14,412,979||--|
|Deferred financing and offering costs||64,105||1,369,281|
|Property and equipment, net||1,473,483||1,146,599|
|Total assets||$ 49,312,187||$ 8,728,246|
|June 30,||December 31,|
|Liabilities and stockholders' equity (deficit)|
|Accounts payable||$ 1,192,786||$ 948,429|
|Total current liabilities||3,437,938||3,303,142|
|Redeemable convertible preferred stock warrant liability||—||730,543|
|Term loan payable - non-current, net of discount||9,669,319||9,705,655|
|Nuvogen obligation - non-current, net of discount||8,674,360||8,677,859|
|Total redeemable convertible preferred stock||(2)||—||55,922,593|
|Commitments and Contingencies|
|Total stockholders' equity (deficit)||(2)(3)||27,486,813||(69,669,926)|
|Total liabilities and stockholders' equity (deficit)||$ 49,312,187||$ 8,728,246|
(1) Reflects net IPO proceeds
(2) Reflects conversion of redeemable convertible preferred stock into common and issuance of shares in our IPO.
(3) Reflects issuance of shares in our IPO
CONTACT: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: email@example.com TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: firstname.lastname@example.orgNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...